STOCK TITAN

BioMarin to Participate in Two Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical announced participation in two virtual investor conferences on February 16, 2022.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

BioMarin Pharmaceutical announced participation in two virtual investor conferences on February 16, 2022. The management will present, and a live audio webcast of the presentations can be accessed at the official website. An archived version will also be available after the events. BioMarin, focusing on innovative therapies for serious rare disorders, has a diverse portfolio with seven commercial products. For more details, visit www.biomarin.com.

Loading...
Loading translation...
Argus Session date unavailable
-2.58% session move Open Argus
Details

News Market Reaction – BMRN

The recorded move for BMRN in the trading session of this news was -2.58%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

SAN RAFAEL, Calif., Feb. 16, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences.  An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:


Investors

Media

Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558 

(415) 455-7451

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-two-upcoming-virtual-investor-conferences-301484038.html

SOURCE BioMarin Pharmaceutical Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the dates of the upcoming virtual conferences for BioMarin (BMRN)?

The virtual conferences are scheduled for February 16, 2022.

How can I access the audio webcast of BioMarin's presentations?

You can access the audio webcast at the official BioMarin website.

What is the focus of BioMarin Pharmaceutical's work?

BioMarin develops therapies for serious and life-threatening rare disorders.

How many commercial products does BioMarin have?

BioMarin has seven commercialized products.

Where can I find more information about BioMarin Pharmaceutical (BMRN)?

More information is available on BioMarin's website at www.biomarin.com.

Keep reading